GLP-1 Agonists and Muscle Mass — Preserving Lean Tissue During Weight Loss

GLP-1 receptor agonists have transformed obesity treatment. Semaglutide, tirzepatide, and newer agents like retatrutide produce weight loss that was previously achievable only through bariatric surgery. But weight loss is not a single metric — what you lose matters as much as how much you lose. Clinical trial data consistently show that a meaningful portion of the weight lost on these therapies is lean tissue, not just fat. Understanding this trade-off, and what can be done to mitigate it, is essential for making informed decisions about GLP-1 therapy.

This article is educational content and does not constitute medical advice. Consult a qualified healthcare professional before starting or modifying any treatment.

The lean mass loss problem

All weight loss — regardless of method — involves some loss of lean tissue. This is a basic physiological reality. When the body enters a caloric deficit, it draws energy from both fat stores and muscle protein. The ratio depends on the magnitude of the deficit, the speed of weight loss, the degree of physical activity, and the individual's starting body composition.

In conventional caloric restriction, lean mass typically accounts for roughly 25% of total weight lost. The concern with GLP-1 agonists is that the profound appetite suppression they produce can push this ratio higher, particularly when patients are not engaged in structured resistance exercise or consuming adequate protein.

What the clinical trials show

Body composition substudies from the major GLP-1 trials have provided increasingly detailed data on this question. The results vary by agent, dose, and study design, but the overall pattern is consistent: lean tissue loss is a real and clinically meaningful phenomenon.

Semaglutide: STEP trial body composition data

The STEP program — the landmark trial series for semaglutide 2.4 mg — included body composition assessments using dual-energy X-ray absorptiometry (DXA) in a subset of participants. In the STEP 1 trial, participants lost an average of approximately 15% of their body weight over 68 weeks.

DXA data from STEP 1 showed that roughly 40% of total weight lost was lean mass, with the remaining 60% being fat mass. This ratio is notably higher than what is typically observed with diet-induced weight loss alone. A subsequent analysis from STEP 3 reported similar proportions, with lean tissue comprising approximately 35-39% of total weight lost.

These numbers have drawn clinical attention. Losing 15% of body weight is metabolically significant, but if nearly 40% of that is lean tissue — including skeletal muscle — the downstream consequences for metabolic rate, physical function, and long-term weight maintenance become a legitimate concern.

Evidence quality: Moderate to strong. DXA substudies from randomized controlled trials, though substudy populations were smaller than the full trial cohorts.

Tirzepatide: dual agonism and body composition

Tirzepatide acts on both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. The dual mechanism produces greater weight loss than semaglutide in head-to-head comparisons — up to 20-25% body weight reduction in the SURMOUNT trials — and has prompted questions about whether the body composition profile differs.

SURMOUNT body composition substudies

Body composition analyses from the SURMOUNT program suggest that tirzepatide may produce a somewhat more favorable lean-to-fat mass loss ratio compared to semaglutide. In SURMOUNT-1, DXA data indicated that lean mass accounted for approximately 25-33% of total weight lost, with the majority being fat mass. Some analyses reported that tirzepatide preferentially reduced visceral fat, a metabolically harmful fat depot.

The GIP receptor component is hypothesized to play a role here. GIP signaling has been linked to lipid metabolism and adipose tissue biology in ways that may influence how the body partitions energy during weight loss. However, the mechanistic evidence for GIP-mediated muscle preservation is still largely preclinical, and the clinical differences between agents in lean mass preservation have not been established in direct head-to-head body composition comparisons.

Evidence quality: Moderate. DXA substudies from major RCTs, but comparisons to semaglutide are indirect and subject to differences in study populations and methodology.

Retatrutide: the triple agonist

Retatrutide targets three receptors — GLP-1, GIP, and glucagon. The glucagon receptor component is the key differentiator. Glucagon promotes lipolysis (fat breakdown), hepatic fat oxidation, and thermogenesis, which has generated interest in whether triple agonism might produce a more favorable body composition outcome — more fat loss, less muscle loss.

Early body composition data

Phase 2 trial data for retatrutide showed weight loss of up to 24% at the highest dose over 48 weeks. Preliminary body composition assessments suggest that the lean-to-fat mass loss ratio may be more favorable than with GLP-1 mono-agonists, potentially because the glucagon component drives preferential fat mobilization and energy expenditure. However, these data come from a relatively small phase 2 trial, and confirmatory phase 3 body composition studies are ongoing.

The glucagon component also raises theoretical concerns. Glucagon can promote amino acid catabolism and gluconeogenesis from muscle-derived substrates, which could work against muscle preservation under certain conditions. Whether the net effect is positive or negative for lean mass likely depends on dose, nutritional context, and physical activity.

Evidence quality: Preliminary. Phase 2 data only; phase 3 body composition outcomes are not yet available.

Why lean mass loss matters

The clinical significance of lean tissue loss extends beyond aesthetics. Skeletal muscle is a metabolically active organ with critical roles in glucose metabolism, functional independence, and long-term health.

Metabolic rate and weight regain

Lean mass is the primary driver of resting metabolic rate. Losing muscle during weight loss reduces daily energy expenditure, which narrows the caloric deficit and contributes to the well-documented phenomenon of metabolic adaptation — the body's decreased energy requirements following weight loss. This metabolic slowing is a major factor in weight regain after therapy discontinuation.

Functional capacity and sarcopenia risk

For older adults and those with limited baseline muscle mass, the loss of lean tissue during GLP-1 therapy raises concerns about sarcopenia — the age-related loss of muscle mass and function that is associated with falls, fractures, disability, and mortality. A 60-year-old who loses 15% of body weight but 40% of that from lean tissue may end up in a worse functional state than before, even if metabolic markers improve.

Glucose disposal and insulin sensitivity

Skeletal muscle is the primary site of insulin-stimulated glucose uptake. Losing muscle mass can paradoxically impair insulin sensitivity even as total body weight decreases, partially offsetting the metabolic benefits of fat loss.

Strategies to preserve lean mass during GLP-1 therapy

The evidence supports several interventions that can shift the lean-to-fat mass loss ratio in a more favorable direction.

Resistance training

Resistance exercise is the single most effective intervention for preserving lean mass during caloric restriction. Studies of resistance training during pharmacological weight loss consistently show reduced lean tissue loss compared to weight loss without structured exercise.

The mechanism is straightforward: mechanical loading signals the body to retain skeletal muscle protein even in a catabolic state. This signal operates through the mTOR (mechanistic target of rapamycin) pathway, stimulating muscle protein synthesis and counteracting the catabolic drive of caloric deficit.

Current evidence supports performing resistance training at least 2-3 sessions per week, targeting all major muscle groups, with progressive overload as a guiding principle.

Protein intake

Adequate protein intake is critical during weight loss to provide the amino acid substrate needed for muscle protein synthesis. General weight loss guidelines recommend protein intake of 1.2-1.6 grams per kilogram of body weight per day — significantly higher than the standard recommended dietary allowance of 0.8 g/kg/day.

For individuals on GLP-1 agonists, meeting these protein targets can be challenging. The profound appetite suppression these drugs produce means total caloric intake is often dramatically reduced. If protein is not prioritized within that reduced intake, patients may consume insufficient amino acids to support muscle maintenance.

Practical strategies include prioritizing protein at each meal, consuming protein-rich foods first, and potentially using protein supplementation when appetite is significantly suppressed.

Combining resistance training and protein

The combination of resistance exercise and high protein intake is additive. Studies in caloric restriction without pharmacotherapy show that this combination can reduce lean mass loss to as little as 10-15% of total weight lost, compared to 25-40% with diet alone.

The role of concurrent exercise: what the research shows

Dedicated studies examining exercise combined with GLP-1 therapy are still limited, but the available data are encouraging. A study examining semaglutide combined with supervised exercise found that participants who exercised preserved significantly more lean mass than those on semaglutide alone, while achieving comparable or greater fat loss.

Aerobic exercise alone provides some lean mass preservation benefit but is substantially less effective than resistance training for this purpose. The ideal approach appears to be a combination of resistance training (for direct muscle preservation) and moderate aerobic activity (for cardiovascular health and additional fat oxidation), performed consistently throughout the course of GLP-1 therapy.

It is worth noting that exercise adherence can be challenging during the early weeks of GLP-1 therapy, when gastrointestinal side effects such as nausea are most common. A gradual ramp-up of exercise intensity, aligned with the dose titration schedule, is a practical approach.

Practical considerations and limitations

Several important caveats apply to the body composition data discussed above.

DXA limitations. DXA measures lean mass, not specifically skeletal muscle. Lean mass includes water, connective tissue, and organ mass. Changes in hydration status — which are common during rapid weight loss — can affect DXA-derived lean mass estimates, potentially overstating true muscle loss.

Individual variation. Body composition responses to GLP-1 therapy vary substantially between individuals. Age, sex, baseline muscle mass, physical activity level, protein intake, and genetic factors all influence the lean-to-fat mass loss ratio.

Long-term data gaps. Most body composition data come from trials lasting 52-72 weeks. The long-term trajectory of lean mass during extended therapy — and particularly during weight maintenance phases — is not well characterized.

No standardized guidelines. As of mid-2026, there are no formal clinical guidelines specifically addressing lean mass preservation during GLP-1 agonist therapy. The recommendations above are extrapolated from general weight management evidence and emerging GLP-1-specific data.

Conclusion

GLP-1 receptor agonists deliver transformative weight loss, but the composition of that weight loss matters. Clinical data from semaglutide, tirzepatide, and early retatrutide trials consistently show that lean tissue accounts for a meaningful fraction of total weight lost — a reality with implications for metabolic health, physical function, and long-term outcomes.

The available evidence strongly supports combining GLP-1 therapy with resistance training and adequate protein intake (1.2-1.6 g/kg/day) to shift the balance toward fat loss and away from muscle loss. These are not optional add-ons — for most patients, they should be considered essential components of a comprehensive weight management plan.

As body composition data from ongoing phase 3 trials mature, the field will develop a clearer picture of how different GLP-1, dual, and triple agonists compare in their effects on lean tissue. Until then, the practical prescription is clear: if you are losing weight on a GLP-1 agonist, lift weights and eat enough protein.

This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider before making decisions about medications or therapeutic protocols.